Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies.

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Annum Maha, Mohsin Ali, Hajira Bilal, Muhammad Imran Khokhar, Abdul Muqeet Khan, Rabia Khokhar, Ijaz Alvi, Mamoona Tariq, Mian Waqar Mustafa, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Muhammad Usman
{"title":"Population pharmacokinetics of linezolid among post-operative patients: Implications for dosing strategies.","authors":"Annum Maha, Mohsin Ali, Hajira Bilal, Muhammad Imran Khokhar, Abdul Muqeet Khan, Rabia Khokhar, Ijaz Alvi, Mamoona Tariq, Mian Waqar Mustafa, Walaa F Alsanie, Abdulhakeem S Alamri, Majid Alhomrani, Muhammad Usman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Linezolid is a synthetic antibiotic and produces its antibacterial effect by inhibiting protein synthesis. It is used to treat life-threatening infections caused by MRSA and VRE. Linezolid clearance occurs through both the renal and hepatic routes. The identification of factors associated with linezolid clearance is required in Pakistani patients. A total of 215 samples from 59 post-operative patients were collected from a tertiary care hospital after a first dose of linezolid. The data was used to develop a population pharmacokinetic (popPK) model by using NONMEM® software. Analysis of the available covariates on pharmacokinetic parameters of linezolid was performed by using stepwise covariate modeling approach, A one-compartment model described the popPK and the value for linezolid clearance (CL) was 3.72 L/h while that of volume of distribution (Vd) was 36.9 L. The interindividual variability on linezolid CL was 36.5%. During stepwise covariate analysis, creatinine clearance (CRCL) was proved to be a significant covariate on CL. This is concluded that the clearance of linezolid is influenced by the renal status of patients and there is a dire need for dose optimization of linezolid in Pakistani patients based on renal status in order to avoid toxicity and adverse drug effects.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"38 1","pages":"291-298"},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Linezolid is a synthetic antibiotic and produces its antibacterial effect by inhibiting protein synthesis. It is used to treat life-threatening infections caused by MRSA and VRE. Linezolid clearance occurs through both the renal and hepatic routes. The identification of factors associated with linezolid clearance is required in Pakistani patients. A total of 215 samples from 59 post-operative patients were collected from a tertiary care hospital after a first dose of linezolid. The data was used to develop a population pharmacokinetic (popPK) model by using NONMEM® software. Analysis of the available covariates on pharmacokinetic parameters of linezolid was performed by using stepwise covariate modeling approach, A one-compartment model described the popPK and the value for linezolid clearance (CL) was 3.72 L/h while that of volume of distribution (Vd) was 36.9 L. The interindividual variability on linezolid CL was 36.5%. During stepwise covariate analysis, creatinine clearance (CRCL) was proved to be a significant covariate on CL. This is concluded that the clearance of linezolid is influenced by the renal status of patients and there is a dire need for dose optimization of linezolid in Pakistani patients based on renal status in order to avoid toxicity and adverse drug effects.

利奈唑胺在术后患者中的群体药代动力学:对给药策略的影响。
利奈唑胺是一种合成抗生素,其抑菌作用是通过抑制蛋白质合成而产生的。它用于治疗MRSA和VRE引起的危及生命的感染。利奈唑胺的清除可通过肾脏和肝脏途径进行。巴基斯坦患者需要确定与利奈唑胺清除率相关的因素。第一次给药利奈唑胺后,从一家三级医院收集了59例术后患者的215份样本。采用NONMEM®软件建立群体药代动力学(popPK)模型。采用逐步协变量建模方法对利奈唑胺药动学参数进行协变量分析,popPK为单室模型,利奈唑胺清除率(CL)为3.72 L/h,分布容积(Vd)为36.9 L,利奈唑胺的个体间变异性为36.5%。在逐步协变量分析中,肌酐清除率(CRCL)被证明是CL的显著协变量。综上所述,利奈唑胺的清除率受患者肾脏状况的影响,巴基斯坦患者迫切需要根据肾脏状况优化利奈唑胺的剂量,以避免毒性和药物不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
211
审稿时长
4.5 months
期刊介绍: Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer reviewed multi-disciplinary pharmaceutical sciences journal. The PJPS had its origin in 1988 from the Faculty of Pharmacy, University of Karachi as a biannual journal, frequency converted as quarterly in 2005, and now PJPS is being published as bi-monthly from January 2013. PJPS covers Biological, Pharmaceutical and Medicinal Research (Drug Delivery, Pharmacy Management, Molecular Biology, Biochemical, Pharmacology, Pharmacokinetics, Phytochemical, Bio-analytical, Therapeutics, Biotechnology and research on nano particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信